早期大剂量促红细胞生成素用于早产儿或低出生体质量儿的Meta分析

目的比较早期大剂量促红细胞生成素(EPO)用于早产儿(出生时胎龄<37周的新生儿)或低出生体质量儿(出生体质量<1500 g的新生儿)的有效性及安全性。方法计算机检索PubMed,EMbase,The Cochrane Library,CNKI,VIP和WanFang Data数据库,分析早期大剂量EPO用于早产儿或低出生体质量儿的随机对照试验(RCT)。结果共纳入37个研究,3432例患者;Meta分析结果显示,与对照组比较,早期大剂量应用EPO能有效降低早产儿或低出生体质量儿的输血率,并能降低坏死性小肠结肠炎发生率。结论现有证据表明,早期大剂量应用EPO能有效降低早产儿或低出生体质量儿的输血率、输血次数及坏死性小肠结肠炎发生率。

Objective To compare the efficacy and safety of early high-dose erythropoietin(EPO)in preterm infants(gestational age<37 weeks)or low birth weight infants(birth weight<1500 g).Methods PubMed,EMBASE,the Cochrane Library,CNKI,VIP and WanFang databases were searched to analyze the randomized controlled trials(RCTs)of early high-dose EPO in preterm infants or low birth weight infants.Results A total of 37 studies involving 3432 patients were included.The results of Meta-analysis showed that compared with the control group,early high-dose EPO can effectively reduce the blood transfusion rate of premature infants or low birth weight infants,and reduce the incidence of necrotizing enterocolitis.Conclusion The existing evidence shows that early high-dose EPO can effectively reduce the rate of blood transfusion,the number of blood transfusion and the incidence of necrotizing enterocolitis in premature or low birth weight infants.